86
Participants
Start Date
September 1, 2020
Primary Completion Date
May 19, 2022
Study Completion Date
May 31, 2022
Pegozafermin
Subcutaneous injection
Placebo
Matching placebo
89Bio Clinical Study Site, Budapest
89Bio Clinical Study Site, Miskolc
89Bio Clinical Study Site, Debrecen
89Bio Clinical Study Site, Békéscsaba
89Bio Clinical Study Site, Albany
89Bio Clinical Study Site, Prague
89Bio Clinical Study Site, Manassas
89Bio Clinical Study Site, Greensboro
89Bio Clinical Study Site, Morganton
89Bio Clinical Study Site, Summerville
89Bio Clinical Study Site, Lawrenceville
89Bio Clinical Study Site, Jacksonville
89Bio Clinical Study Site, Orlando
89Bio Clinical Study Site, Miami Lakes
89Bio Clinical Study Site, Miami Lakes
89Bio Clinical Study Site, Miami
89Bio Clinical Study Site, Miami
89Bio Clinical Study Site, North Miami Beach
89Bio Clinical Study Site, Greenacres City
89Bio Clinical Study Site, Tampa
89Bio Clinical Study Site, Clearwater
89Bio Clinical Study Site, Chattanooga
89Bio Clinical Study Site, Kingsport
89Bio Clinical Study Site, Olive Branch
89Bio Clinical Study Site, Louisville
89Bio Clinical Study Site, Marion
89Bio Clinical Study Site, West Des Moines
89Bio Clinical Study Site, Wauconda
89Bio Clinical Study Site, Quincy
89Bio Clinical Study Site, Dallas
89Bio Clinical Study Site, Lampasas
89Bio Clinical Study Site, Houston
89Bio Clinical Study Site, Magnolia
89Bio Clinical Study Site, Dallas
89Bio Clinical Study Site, Austin
89Bio Clinical Study Site, La Mesa
89Bio Clinical Study Site, San Francisco
89Bio Clinical Study Site, Pardubice
89Bio Clinical Study Site, Prague
89Bio Clinical Study Site, Prague
89Bio Clinical Study Site, Prague
89Bio Clinical Study Site, Baja
89Bio Clinical Study Site, Bialystok
89Bio Clinical Study Site, Bialystok
89Bio Clinical Study Site, Lodz
89Bio Clinical Study Site, Oświęcim
89Bio Clinical Study Site, Rzeszów
89Bio Clinical Study Site, Torun
Lead Sponsor
89bio, Inc.
INDUSTRY